Genmab — November 2018
-
@Lego,17.05. Vel naturligt der skal nyt til fra pipelinen for Darzalex er ikke en evighedsmaskine. Selv Jan siger at udviklingen indenfor cancer går ufattelige hurtigt så hvis Genmab ikke er hurtige nok er det jo lidt som at skyde sig selv i foden med en sådan udtalelse. Pesoonlige tror jeg Jan har en god case men det tror markedet tilsynelanende ikke
-
-
Det Jan skriver her”Jan Van de Winkel
Revenue DKK 1.789 bn up DKK 441 Mio. Expenses DKK 1.130 bn, up DKK 423 (or DKK 282 after reimbursement from partners). Operating result DKK 659 mio, up DKK 18 mio and net result DKK 638 mio, up DKK 320 mio...” -
Gør vel også at net resultat for 2018 ml 1200-1500 mio kr bliver svært at nå, eller hvad siger I
-
Rettelse:
årsmål var 1300-1500 mio kr -
Så skal der tjenes 662 mio kr i q4. Er det realistisk? Hvor meget milestone mangler det?
-
der mangler ihvertfald en på omkring 50 millioner dollars, men det kræver, at vi når over 2B $ inden nytår
-
-
God morgen
-
Good morning, A small study (Dara after stem cell transplant) has been withdrawn. https://clinicaltrials.gov/ct2/history/NCT03346135?A=3&B=4&C=Side-by-Side
-
-
@Sukkeralf on the back of your CD3 question; did you see the resumption of the CD3xCD123 trial as shown by gentogen?
https://clinicaltrials.gov/ct2/show/NCT02715011?term=JNJ-63709178&rank=1
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind